Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance
Recruiting · NCT07257562 · Observational (researchers observe without assigning treatment) · Lead sponsor: First Affiliated Hospital of Fujian Medical University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance. The study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.
Who can take part
Inclusion criteria
- \- chronic hepatitis B patients
Exclusion criteria
- patients with malignancies
- patients with other liver diseases
- pregnancy patients
Where it is running
1 location listed.
- The First Affiliated Hospital of Fujian Medical University - Fuzhou, Fujian, China